Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CAPTW
14301
DELISTED
Captivision Inc Warrant
CAPTW
| $352 | ﹤0.01% |
35,229
-2,480
| -7% | -$58 |
2023 Q4
4 quarters
|
|
14302
PUT
Marchex
MCHX
$57.2M
| $350 | ﹤0.01% |
200
-1,800
| -90% | -$3.32K |
2024 Q3
1 quarter
|
|
|
CBIO
14303
PUT
Crescent Biopharma
CBIO
$532M
| $349 | ﹤0.01% |
+14
| New | +$382 |
2024 Q4
0 quarters
|
|
14304
PUT
TherapeuticsMD
TXMD
$23.7M
| $344 | ﹤0.01% |
400
-6,700
| -94% | -$9.43K |
2017 Q2
30 quarters
|
|
|
SVMHW
14305
DELISTED
SRIVARU Holding Limited Warrant
SVMHW
| $329 | ﹤0.01% |
38,740
-1,010
| -3% | -$9 |
2023 Q4
4 quarters
|
|
14306
PUT
Neuronetics
STIM
$165M
| $322 | ﹤0.01% |
+200
| New | +$208 |
2024 Q4
0 quarters
|
|
|
MKFG
14307
CALL
DELISTED
Markforged Holding Corporation
MKFG
| $314 | ﹤0.01% |
100
-5,900
| -98% | -$24.8K |
2024 Q2
2 quarters
|
|
|
SLSR
14308
PUT
Solaris Resources
SLSR
$1.18B
| $311 | ﹤0.01% |
+100
| New | +$270 |
2024 Q4
0 quarters
|
|
14309
CALL
GSI Technology
GSIT
$216M
| $303 | ﹤0.01% |
100
-5,900
| -98% | -$18.6K |
2024 Q3
1 quarter
|
|
|
NVNO
14310
PUT
enVVeno Medical
NVNO
$5.63M
| $302 | ﹤0.01% |
3
-146
| -98% | -$16.3K |
2023 Q4
4 quarters
|
|
|
PHLT
14311
PUT
DELISTED
Performant Healthcare Inc
PHLT
| $302 | ﹤0.01% |
100
-21,500
| -100% | -$73.9K |
2024 Q3
1 quarter
|
|
14312
Immunic
IMUX
$109M
| $300 | ﹤0.01% |
30
-23,976
| -100% | -$302K |
2024 Q1
3 quarters
|
|
14313
PUT
Pixelworks
PXLW
$42.5M
| $292 | ﹤0.01% |
+33
| New | +$299 |
2024 Q4
0 quarters
|
|
14314
PUT
Usio Inc
USIO
$83.5M
| $292 | ﹤0.01% |
+200
| New | +$283 |
2024 Q4
0 quarters
|
|
14315
PUT
Hydrofarm Holdings
HYFM
$4.96M
| $290 | ﹤0.01% |
+50
| New | +$327 |
2024 Q4
0 quarters
|
|
|
VIRX
14316
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $290 | ﹤0.01% |
+1,800
| New | +$354 |
2024 Q4
0 quarters
|
|
14317
CALL
Skye Bioscience
SKYE
$7.44M
| $283 | ﹤0.01% |
13
-1,000
| -99% | -$33.4K |
2024 Q2
2 quarters
|
|
|
HYMCL
14318
DELISTED
Hycroft Mining Holding Corp Warrants
HYMCL
| $275 | ﹤0.01% |
18,997
-32,969
| -63% | -$729 |
2023 Q3
5 quarters
|
|
14319
Revelation Biosciences Warrant
REVBW
| $268 | ﹤0.01% |
38,235
+8,835
| +30% | +$103 |
2023 Q1
7 quarters
|
|
14320
PUT
Genasys
GNSS
$66M
| $260 | ﹤0.01% |
100
| – | – |
2024 Q3
1 quarter
|
|
|
NLSPW
14321
DELISTED
NLS Pharmaceutics Warrant
NLSPW
| $246 | ﹤0.01% |
18,958
-668
| -3% | -$8 |
2024 Q2
2 quarters
|
|
|
COEPW
14322
DELISTED
Coeptis Therapeutics Warrants
COEPW
| $245 | ﹤0.01% |
11,145
-638
| -5% | -$15 |
2024 Q1
3 quarters
|
|
|
AXDX
14323
CALL
DELISTED
Accelerate Diagnostics
AXDX
| $240 | ﹤0.01% |
+200
| New | +$332 |
2024 Q4
0 quarters
|
|
|
KPLTW
14324
DELISTED
Katapult Holdings Warrant
KPLTW
| $232 | ﹤0.01% |
28,974
-3,232
| -10% | -$21 |
2024 Q3
1 quarter
|
|
|
PTN
14325
CALL
Palatin Technologies
PTN
$16.6M
| $222 | ﹤0.01% |
4
-226
| -98% | -$11.4K |
2023 Q2
6 quarters
|
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.